Open AccessMini-review: The market growth of diagnostic and therapeutic monoclonal antibodies – SARS CoV-2 as an example
Author(s) -
Y El,
Ashraf A. Tabll,
Robert Stoehr,
Martina Smolić
Publication year - 2022
Publication title -
human antibodies
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.274
H-Index - 24
eISSN - 1875-869X
pISSN - 1093-2607
DOI - 10.3233/hab-211513
Subject(s) - monoclonal antibody , antibody , immunotherapy , virology , biopharmaceutical , medicine , covid-19 , immunology , epitope , immune system , disease , infectious disease (medical specialty) , biology , microbiology and biotechnology
BACKGROUND: The emergence of novel viruses poses severe challenges to global public health highlighting the crucial necessity for new antivirals. MAIN BODY: Monoclonal antibodies (mAbs) are immunoglobulins that bind to a single epitope. Mouse mAbs are generated by classic hybridoma technology and are mainly used for immunodiagnostics. For immunotherapy, it is critical to use monoclonal antibodies in their human form to minimize adverse reactions. They have been successfully used to treat numerous illnesses, accordingly, an increasing number of mAbs, with high potency against emerging viruses is the target of every biopharmaceutical company. The diagnostic and therapeutic mAbs market grows rapidly into a multi-billion-dollar business. Biopharmaceuticals are innovative resolutions which revolutionized the treatment of significant chronic diseases and malignancies. Currently, a variety of therapeutic options that include antiviral medications, monoclonal antibodies, and immunomodulatory agents are available for the management of COVID-19. SHORT CONCLUSION: The invasion of mAbs in new medical sectors will increase the market magnitude as it is expected to generate revenue of about 300 billion $ by 2025. In the current mini-review, the applications of monoclonal antibodies in immune-diagnosis and immunotherapy will be demonstrated, particularly for COVID-19 infection and will focus mainly on monoclonal antibodies in the market.